Long-Term Monitoring and Your Child's Future
At a Glance
With early, consistent biotin treatment and regular follow-up, many children with holocarboxylase synthetase (HLCS) deficiency grow and develop well. Ongoing metabolic, developmental, hearing, and illness monitoring supports a healthy future.
The diagnosis of Holocarboxylase Synthetase (HLCS) deficiency is lifelong, but the outlook for many children is optimistic. When treatment starts early and is followed strictly, many children grow and develop steadily alongside their peers [1][2].
Long-Term Outlook and Development
For children who receive prompt biotin treatment, the clinical trajectory is often highly favorable.
- Physical and Mental Growth: Studies of children treated since infancy show they frequently achieve near-normal height, weight, and development, and frequently meet all their major developmental milestones on time [1][3][4].
- Stability: With daily biotin, many children achieve stable health and avoid the dangerous metabolic crises described in earlier sections [5][1]. However, outcomes depend heavily on disease severity, the child’s specific genetic profile, and whether any neurologic injury occurred before treatment began.
- Educational Support: Children should receive ordinary developmental surveillance. Any delay, regression, seizure, hearing concern, or change in behavior should prompt clinical review by your pediatrician and metabolic team, rather than being automatically attributed to HLCS deficiency alone.
Ongoing Monitoring and Care
Even when a child is doing well, they need regular follow-up with a metabolic genetics team. The metabolic team will set the specific schedule and determine which tests are necessary based on your child’s phenotype and treatment response.
Your individualized monitoring plan may include:
- Metabolic Lab Work: Periodic blood and urine tests to check levels of lactate, ammonia, and specific markers like 3-hydroxyisovaleric acid [6][7]. This is distinct from testing done during a crisis.
- Growth and Nutrition: Regular checks of height and weight. Children generally do not need a special protein-restricted diet unless specifically prescribed by the metabolic team; the key is regular intake and avoiding prolonged fasting [1].
- Neurological Checks: Monitoring for any changes in muscle tone or seizures [6].
- Hearing and Vision: Because some children may experience hearing damage, baseline and periodic hearing screens are often recommended [8][1].
- Dermatology: Persistent skin rashes or hair loss that do not fully resolve with biotin may require specialized skin care [9].
Thinking About the Future: Family Planning
HLCS deficiency is an autosomal recessive condition. This means that for your child to have the condition, both parents must be “carriers” of a non-working copy of the HLCS gene [5].
- Recurrence Risk: For parents who are both carriers, there is a 25% (1 in 4) chance with each future pregnancy that the baby will also have HLCS deficiency [5].
- Sibling Testing: Because newborn screening can occasionally miss a case [10], experts often recommend prompt targeted familial-variant testing or appropriate biochemical testing for all at-risk siblings—especially infants—even if they appear perfectly well [11].
- Genetic Counseling: A genetic counselor can help you understand these risks and discuss options for family planning, such as preconception genetic testing, metabolic consultation, and obstetric care planning [8][12][13].
A Life of Management, Not Limitation
While your child will always need to take biotin, be extra careful during illnesses, and alert clinicians to laboratory interferences, this diagnosis does not prevent a rich and full life. By staying consistent with treatment and following the individualized illness plan, you are giving your child the foundation they need to thrive [1][3].
Common questions in this guide
What is the long-term outlook for a child with HLCS deficiency?
What follow-up tests does a child with HLCS deficiency need?
Does a child with HLCS deficiency need a special diet?
Should my child have regular hearing tests?
What is the chance that another child will have HLCS deficiency?
Should healthy brothers or sisters be tested for HLCS deficiency?
How is HLCS deficiency care transitioned as my child becomes an adult?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our specific schedule for follow-up labs, growth checks, and clinical monitoring?
- 2.Are there specific developmental or educational milestones we should be monitoring more closely?
- 3.Does my child need a baseline hearing test or periodic hearing screenings?
- 4.If we are planning to have more children, can you help us arrange targeted carrier testing?
- 5.What is the recommended plan for transitioning my child's metabolic care as they grow into adulthood?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Clinical, biochemical, and genetic analysis of 28 Chinese patients with holocarboxylase synthetase deficiency.
Ling S, Qiu W, Zhang H, et al.
Orphanet journal of rare diseases 2023; (18(1)):48 doi:10.1186/s13023-023-02656-y.
PMID: 36890565 - 2
Dramatic Clinical Improvement With Biotin Mega-Dose Therapy in a Neonate With Holocarboxylase Synthetase Deficiency.
Kim SW, Lee HJ, Choi N, et al.
Molecular genetics & genomic medicine 2024; (12(8)):e70002 doi:10.1002/mgg3.70002.
PMID: 39194177 - 3
Holocarboxylase Synthetase Deficiency: Clinical, Biochemical and Molecular Findings in Five Malaysian Patients Including a Newborn Presenting as Collodion Baby.
Ting SL, Yakob Y, Sani HA, et al.
JIMD reports 2025; (66(2)):e70006 doi:10.1002/jmd2.70006.
PMID: 40051682 - 4
Case report of holocarboxylase synthetase deficiency (late-onset) in 2 Chinese patients.
Xiong Z, Zhang G, Luo X, et al.
Medicine 2020; (99(18)):e19964 doi:10.1097/MD.0000000000019964.
PMID: 32358368 - 5
Holocarboxylase synthetase deficiency: pathogenesis, clinical features, diagnosis, treatment, and research prospects.
ZeZhao J, Ablimit A
European journal of pediatrics 2026; (185(7)).
PMID: 42324336 - 6
Holocarboxylase synthetase deficiency pre and post newborn screening.
Donti TR, Blackburn PR, Atwal PS
Molecular genetics and metabolism reports 2016; (7()):40-4 doi:10.1016/j.ymgmr.2016.03.007.
PMID: 27114915 - 7
Impaired glucose homeostasis and a novel HLCS pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review.
Wu HR, Chen KJ, Hsiao HP, Chao MC
Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(11)):1481-1486.
PMID: 32841162 - 8
Clinical, biochemical, and genetic analysis of a Chinese Han pedigree with holocarboxylase synthetase deficiency: a case report.
Zheng Z, Yuan G, Zheng M, et al.
BMC medical genetics 2020; (21(1)):155 doi:10.1186/s12881-020-01080-4.
PMID: 32727382 - 9
Successful treatment with secukinumab of psoriasis-like dermatitis in a patient with holocarboxylase synthetase deficiency.
Liu H, Wei R, Yang Y, et al.
The Journal of dermatology 2023; (50(3)):401-406 doi:10.1111/1346-8138.16625.
PMID: 36342067 - 10
Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Congenital and Developmental Disorders.
Abacan MAR, Baltazar-Braganza KR, Cabaluna ITG, et al.
Acta medica Philippina 2026; (60(10)):28-41 doi:10.47895/amp.v60i10.10675.
PMID: 42382931 - 11
Case report: Two siblings with very late onset of holocarboxylase synthase deficiency and a mini-review.
Gaschignard M, Domenach L, Lamireau D, et al.
Frontiers in genetics 2024; (15()):1249480 doi:10.3389/fgene.2024.1249480.
PMID: 39391064 - 12
Paracentric Inversion of Chromosome 21 Leading to Disruption of the HLCS Gene in a Family with Holocarboxylase Synthetase Deficiency.
Quinonez SC, Seeley AH, Lam C, et al.
JIMD reports 2017; (34()):55-61 doi:10.1007/8904_2016_9.
PMID: 27518780 - 13
Successful pregnancy and childbirth without metabolic abnormality in a patient with holocarboxylase synthetase deficiency.
Meguro M, Wada Y, Kisou Y, et al.
Molecular genetics and metabolism reports 2022; (33()):100923 doi:10.1016/j.ymgmr.2022.100923.
PMID: 36245960
This page explains long-term monitoring and family planning for a child with HLCS deficiency for educational purposes only and does not constitute medical advice. Your child's metabolic genetics team should guide monitoring, treatment, and family-planning decisions.
Get notified when new evidence is published on Holocarboxylase synthetase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.